
Belite Bio, Inc American Depositary Shares
BLTE
BLTE: Belite Bio Inc is a clinical-stage biopharmaceutical drug development company focused on novel therapeutics targeting untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease or STGD1, both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease, or NAFLD, nonalcoholic steatohepatitis, or NASH, type 2 diabetes, or T2D, and gout.
moreShow BLTE Financials
Recent trades of BLTE by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by BLTE's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Methods of treating metabolic diseases with fused bicyclic pyrazoles Jul. 19, 2022
-
Patent Title: Methods of treating rbp4 related diseases with triazolopyridines May. 18, 2021
-
Patent Title: Methods of treating rbp4 related diseases with triazolopyridines Apr. 02, 2019
Federal grants, loans, and purchases
Followers on BLTE's company Twitter account
Number of mentions of BLTE in WallStreetBets Daily Discussion
Recent insights relating to BLTE
Recent picks made for BLTE stock on CNBC
ETFs with the largest estimated holdings in BLTE
Flights by private jets registered to BLTE